Cassava Sciences, Inc.

Fact Sheet

SAVA

LISTED

NASDAQ

CASSAVA SCIENCES

QUICK REFERENCE

Cassava Sciences Inc.
NASDAQ: SAVA

Website: **www. CASSAVASCIENCES.com**

BUSINESS SUMMARY

Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

SCIENCE

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer's disease.
Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer's Disease.
We are now in clinical studies to test a new and promising scientific approach for the treatment and diagnosis of Alzheimer's disease. If you are interested in being notified about clinical trials, click here.
Simufilam was developed in-house. Over the years, simufilam has been substantially funded by peer-review research grant awards from the National Institutes of Health (NIH).

SavaDx (formerly known as PTI-125Dx) is our blood-based diagnostic to detect Alzheimer's disease.
The goal of SavaDx is to make the detection of Alzheimer's disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.
We are developing SavaDx as a simple, accurate and quantitative blood-based diagnostic to detect and monitor Alzheimer's disease. If successful, we believe SavaDx has potential to make obsolete many of the current approaches for diagnosing Alzheimer's disease.
In blinded studies, our investigational diagnostic, SavaDx, detected >10-fold differences between patients with Alzheimer's and age-matched normal controls or young cognitively intact subjects (N=232).
This clinical-stage program is funded by research grants from the National Institutes of Health (NIH).

CONTACT INFORMATION

US Headquarters
7801 N. Capital of Texas Highway
Austin, TX 78731

Investor Relations Contact
Andrew Barwicki
516-662-9461/andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Cassava Sciences Reports Second Quarter 2021 Financial Results

Aug. 03, 2021 -- Cassava Sciences, Inc. announced financial results for the second quarter ended June 30, 2021. Net loss for the second quarter ended June 30, 2021, was $5.1 million, or $0.13 per share, compared to a net loss of $1.1 million, or $0.05 per share, for the same period in 2020. Net cash used in operations was $7.4 million during the first six months of 2021. Net cash use for operations for full-year 2021 is expected to be approximately $20 to $25 million, consistent with previous financial guidance. Cash and cash equivalents were $278.3 million as of June 30, 2021, with no debt.

Financial Highlights for Second Quarter 2021-

- At June 30, 2021, cash and cash equivalents were $278.3 million, compared to $93.5 million at December 31, 2020, with no debt.
- Net cash used in operations during the six months ended June 30, 2021 was $7.4 million, net of reimbursements received from the National Institutes of Health (NIH) grant awards.
- Research grant funding reimbursements of $0.9 million were received from NIH and recorded as a reduction in research and development (R&D) expenses. This compared to $1.1 million of NIH grant receipts received for the same period in 2020.
- Net cash use for operations for full year 2021 is expected to be approximately $20 to $25 million. Net cash use in 2021 is expected to be driven by higher headcount and personnel expenses, manufacturing costs around large-scale drug supply, professional services expenses related to clinical programs, and operating costs such as insurance, office space and IT related expenses.
- R&D expenses were $3.9 million compared to $0.6 million for the same period in 2020. This increase was due primarily to costs related to manufacture of clinical trial supplies in anticipation of launching a Phase 3 clinical program in simufilam, costs of an on-going open-label study in simufilam, as well as increased personnel expenses.
- General and administrative (G&A) expenses were $1.2 million compared to $0.8 million for the same period in 2020. This increase was due primarily to higher annual shareholder meeting and insurance costs compared to the prior year.

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease

**** Simufilam Significantly Improves Cognition in Patients with Alzheimer's in Interim Analysis of Open-label Study at 9 Months***

**** Cognition Improved 3.0 Points on ADAS-Cog at 9 Months (p<0.001)***

**** Cognitive Improvements Track with Biomarker Improvements***

**** No Behavior Disorders in Over 50% of Patients***

**** No Safety Issues***

**** Improvements in Cognition, Biomarkers and Behavior Suggest Highly Encouraging Treatment Effects***

July 29, 2021 -- Cassava Sciences, Inc. announced positive clinical data today from an interim analysis of an open-label study with simufilam, the Company's investigational drug for the treatment of Alzheimer's disease.

In a clinical study funded by the National Institutes of Health (NIH), simufilam significantly improved cognition in Alzheimer's patients, with no safety issues. Simufilam improved cognition scores 3.0 points on ADAS-Cog11, an 18% mean improvement, baseline to month 9 (p<0.001). This interim analysis summarizes clinical data from the first 50 patients with mild-to-moderate Alzheimer's disease who completed 9 months of open-label simufilam treatment.

Simufilam improved ADAS-Cog scores in 66% of patients at 9 months. An additional 22% of patients declined less than reported in the science literature at 9 months. Cognition outcomes suggest simufilam's treatment effects were broad-based.

Alzheimer's is often accompanied by behaviors disorders, such as anxiety, agitation or delusions. These may become more frequent as disease progresses. Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Cassava Sciences Inc.

NASDAQ: SAVA

WWW.CASSAVASCIENCES.COM

Barwicki Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: